The Nano Science and Technology Institute (NSTI) is pleased to announce that abstracts are being accepted for the Merck Corporate Symposium: Targeted Delivery of siRNA, to be held during Nanotech 2008 in Boston, MA. The Symposium will provide an important platform for Merck to engage leading researchers in the nano tech community and create a discussion around the application of emerging nano technologies and their ability to affect targeted delivery of therapeutic siRNA molecules.
Merck places a strong emphasis on innovation in all areas of drug research, development and commercialization. "Merck is pleased to partner with the NSTI in bringing this Symposium to Greater Boston, a leading region for the life sciences industry and advanced patient care," said Dr. Reid Leonard, Merck's Executive Director of Licensing and External Research. "Nanotech 2008 reflects our commitment to innovation and provides an ideal forum for the presentation of siRNA enabling technologies – an area where Merck has assumed a leadership role."
NSTI Nanotech 2008 will be held June 1-5 at the Hynes Convention Center in Boston, MA. Entering its 11th year, Nanotech 2008 is the world’s largest and most comprehensive technical and business event in nanotechnology. “Merck’s Corporate Symposium will be one of the highlights of next year’s conference,” noted Dr. Bart Romanowicz, Executive Director of the Nano Science and Technology Institute. “We are delighted that Merck, one of the largest pharmaceutical companies in the world, has partnered with Nanotech 2008 to help address their company’s advanced research needs.”
To participate in the Merck Corporate Symposium, please submit your abstract through the Nanotech On-Line Abstract Submission form by December 6th, 2007: http://www.nsti.org/Nanotech2008/symposia/Merck.html.